The Role of the Emergency Room Physician in the Diagnosis and Management of Neuromyelitis Optica Spectrum Disorder

View Activity


Dean Wingerchuk, MD, MSc, FRCP(C)
Professor and Chair
Department of Neurology
Mayo Clinic
Phoenix/Scottsdale, AZ


Neuromyelitis optica spectrum disorder (NMOSD) is a rare, lifelong and debilitating autoimmune disease of the central nervous system (CNS), characterized by inflammation in the optic nerve and spinal cord. This program will focus on recognizing the symptoms and signs of NMOSD, reviewing best practices for early diagnosis of the disease, and discussing the novel mechanisms of action of new and emerging treatments for NMOSD and clinical trial data on their safety and efficacy profiles.


This activity is designed to meet the educational needs of US-based neurologists, neuroophthalmologists, and emergency physicians who treat patients with NMOSD.


After completing the CME activity, learners should be better able to:

  • Discuss best practices for the early diagnosis of NMOSD including differential diagnosis and AQP4-IgG testing
  • Describe the dysfunctional immunologic factors, such as IL-6, and pathways of clinical importance for NMOSD therapy
  • Review the novel mechanisms of action of emerging treatments for NMOSD and clinical trial data on their safety and efficacy profiles
  • Recognize the signs and symptoms of NMOSD in patients that present in emergency settings


Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.


Med Learning Group designates this web-based activity for a maximum of 1.0 AMA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.


Purpose: This program would be beneficial for nurses who treat patients with NMOSD.
CNE Credits: 1.0 ANCC Contact Hour.


Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

Awarded 1.0 contact hour of continuing nursing education of RNs and APNs.


In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturers of any commercial products and/or providers of commercial services that are discussed in an educational activity.



Dr. Wingerchuk, discloses that he has received consulting fees from MedImmune, Novartis, Biogen, Celgene, Genentech, TG Therapeutics, Arcus Medica, Third Rock Ventures, and Reistone. He also has done contracted research for Alexion and Terumo BCT.

CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.

CNE Content Review
The content of this activity was peer-reviewed by a nurse reviewer.
The reviewer of this activity has nothing to disclose.

The staff, planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:
Russie Allen, Outcomes Coordinator for Med Learning Group has nothing to disclose.
Matthew Frese, General Manager of Med Learning Group has nothing to disclose.
Christina Gallo, SVP, Educational Development for Med Learning Group has nothing to disclose.
Melissa A. Johnson, Senior Program Manager for Med Learning Group has nothing to disclose.
Diana Tommasi, Medical Director, Scientific and Medical Services for Med Learning Group has nothing to disclose.
Lauren K. Welch, VP, Outcomes and Accreditation of Med Learning Group has nothing to disclose.


Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

During this lecture, the faculty may mention the use of medications for both FDA-approved and nonapproved indications.


There are no fees for participating and receiving CME credit for this enduring activity. To receive CME/CNE credit participants must:
1. Read the CME/CNE information and faculty disclosures;
2. Participate in the enduring activity; and
3. Complete pre-and-post surveys and evaluation.

You will receive your certificate after completion of the web-based live activity.


Med Learning Group makes every effort to develop CME activities that are science-based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making ability before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact Med Learning Group at

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at

RELEASE DATE: June 29, 2020

EXPIRATION DATE: June 29, 2021


Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at

View Activity

Copyright © 2020 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.